

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Chaoju Eye Care Holdings Limited

朝聚眼科醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2219)

VOLUNTARY ANNOUNCEMENT

(1) ACQUISITION OF EQUITY INTERESTS IN NINGBO BOSHI EYE HOSPITAL CO., LTD.; AND

(2) ACQUISITION OF EQUITY INTERESTS IN WUZHONG YUNSHIKANG EYE HOSPITAL CO., LTD.

This announcement is made by Chaoju Eye Care Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to keep its shareholders (the “**Shareholders**”) and potential investors informed of the latest business development of the Group.

Acquisition of equity interests in Ningbo Boshi Eye Hospital Co., Ltd.

The board (the “**Board**”) of directors (the “**Directors**”, and each a “**Director**”) of the Company is pleased to announce that recently, Xiamen Xinkangnuo Management Consulting Co., Ltd.* (廈門信康諾管理諮詢有限公司) (“**Xiamen Xinkangnuo**”) and Zhejiang Chaoju Hezhong Investment Management Co., Ltd.* (浙江朝聚和眾投資管理有限公司) (“**Chaoju Hezhong**”), both of which are indirect wholly-owned subsidiaries of the Company, entered into an equity transfer agreement with Tiandirenhe Investment Consulting Co., Ltd.* in Ningbo Meishan Bonded Port Area (寧波梅山保稅港區天地人和投資諮詢有限公司) (“**Tiandirenhe**”), Ms. Zhou Yanhou (“**Ms. Zhou**”), Mr. Mao Chunliang (“**Mr. Mao**”, together with Tiandirenhe and Ms. Zhou, collectively referred to as the “**Original Shareholders of Ningbo Boshi**”), and Ningbo Boshi Eye Hospital Co., Ltd.* (寧波博視眼科醫院有限公司) (“**Ningbo Boshi**”), a subsidiary of the Company. Pursuant to the agreement, Xiamen Xinkangnuo and Chaoju Hezhong intend to acquire 37% equity interests in Ningbo Boshi held by the Original Shareholders of Ningbo Boshi, at a total consideration

of approximately RMB14.04 million (the “**Acquisition I**”). Upon completion of Acquisition I, Ningbo Boshi will become an indirect wholly-owned subsidiary of the Company, and will continue to be consolidated into the financial statements of the Group.

Acquisition of equity interests in Wuzhong Yunshikang Eye Hospital Co., Ltd.

Recently, Xiamen Chaojuleda Holding Co., Ltd.* (廈門朝聚樂達控股有限公司) (“**Leda Holdings**”), an indirect wholly-owned subsidiary of the Company, entered into an equity cooperation agreement with Wuzhong Yunshikang Eye Hospital Co., Ltd.* (吳忠市雲視康眼科醫院有限公司) (“**Yunshikang**”) and its shareholders. Pursuant to the agreement, Leda Holdings intends to acquire 70% equity interests in Yunshikang at a total consideration of approximately RMB4.97 million (“**Acquisition II**”). Upon completion of Acquisition II, Yunshikang will become a subsidiary of the Company, and will be consolidated into the financial statements of the Group.

Reasons for and benefits of the Acquisition

Through the acquisitions of Ningbo Boshi and Yunshikang, the Company will further integrate medical resources in Zhejiang and Ningxia, optimize hospital operational efficiency, expand its hospital service network, and enhance its competitiveness in the local markets. These acquisitions form part of the Company’s established strategic plan. The Company will continue to deepen its presence in the Zhejiang and Ningxia regions, strengthen its industry competitiveness through multi-point deployment, expand its market share, and effectively mitigate market risks.

In light of the above, the Directors are of the view that the terms of Acquisition I and Acquisition II are fair and reasonable, are on normal commercial terms, and are in the interests of the Company and its shareholders as a whole.

Implications under the Listing Rules

In respect of Acquisition I, Tiandirenhe is 35% owned by Mr. Yu Cun (“**Mr. Yu**”), who is a director of Ningbo Boshi, a subsidiary of the Company. As such, Tiandirenhe constitutes a connected person of the Company (as defined under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”)), and the acquisition of equity interests in Ningbo Boshi held by Tiandirenhe by Xiamen Xinkangnuo and Chaoju Hezhong constitutes a connected transaction of the Company under Chapter 14A of the Listing Rules. As all applicable percentage ratios (as calculated pursuant to Rule 14.07 of the Listing Rules) in respect of this connected transaction are below 1%, the Company is not required to disclose the transaction under Chapter 14A of the Listing Rules. To the best knowledge, information and belief of the Directors, having made all reasonable enquiries, save for Tiandirenhe, all other parties involved in Acquisition I and Acquisition II are third parties independent of the Company (as defined under the Listing Rules).

As all applicable percentage ratios (as calculated pursuant to Rule 14.07 of the Listing Rules) in respect of Acquisition I and Acquisition II are below 5%, Acquisition I and Acquisition II do not constitute discloseable transactions of the Company under Chapter 14 of the Listing Rules.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Chaoju Eye Care Holdings Limited
ZHANG Bozhou
Chairman

Hong Kong, June 30, 2025

As at the date of this announcement, the Board of the Company comprises Mr. ZHANG Bozhou as the chairman and executive Director; Ms. ZHANG Xiaoli, Mr. ZHANG Junfeng and Mr. ZHANG Guangdi as executive Directors; Mr. Richard Chen MAO, Mr. LI Zhen and Ms. ZHANG Li as non-executive Directors; and Mr. HE Mingguang, Ms. GUO Hongyan, Mr. LI Jianbin and Mr. BAO Shan as independent non-executive Directors.

** The English translation of the Chinese names denoted in this announcement is for illustration purposes only. Should there be any inconsistencies, the Chinese name shall prevail.*